Brief: Sera Prognostics Announces Positive Top-Line Data From Avert Preterm Trial
15/02/2023 14:26
Feb 15 (Reuters) - Sera Prognostics Inc SERA.O :
* SERA PROGNOSTICS ANNOUNCES POSITIVE TOP-LINE DATA FROM
AVERT
PRETERM TRIAL
* SERA PROGNOSTICS - PRETRM TEST-AND-TREAT STRATEGY
DEMONSTRATES
STATISTICALLY AND CLINICALLY SIGNIFICANT IMPROVEMENT IN NEONATAL
HEALTH OUTCOMES
* SERA PROGNOSTICS INC - BOTH CO-PRIMARY OUTCOMES MET THEIR
ENDPOINTS
Source text for Eikon: ID:nPnbP5n82a
Further company coverage: SERA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Sera Prognostics
See all newsBrief: Sera Prognostics Appoints Scott Gleason Chief Financial Officer
Sera Prognostics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Sera Prognostics Q2 revenue rises on expanded partnerships and Medicaid coverage
Sera Prognostics, Inc. expected to post a loss of 15 cents a share - Earnings Preview
Sera Prognostics Q1 revenue falls sharply, net loss widens